New β-lactamase inhibitors: A therapeutic renaissance in an MDR world

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 1835-1846

  Drawz, Sarah M ^a   Papp Wallace, Krisztina M ^b,c   Bonomo, Robert A ^b,c  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIBACTAM; BETA LACTAMASE INHIBITOR; BORONIC ACID DERIVATIVE; CEFTAROLINE; CEFTAZIDIME; CYCLOBUTANONE DERIVATIVE; MK 7655; RPX 7009; SULFONE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIMICROBIAL ACTIVITY; BACTERIAL GROWTH; BINDING SITE; CHEMICAL STRUCTURE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; ENZYME ACTIVE SITE; ENZYME INHIBITOR COMPLEX; GRAM NEGATIVE INFECTION; IC 50; MASS SPECTROMETRY; MOLECULAR MIMICRY; MYCOBACTERIUM TUBERCULOSIS; NUCLEAR MAGNETIC RESONANCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENZYME INHIBITORS; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 84896968084     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00826-13     Document Type: Review

References (124)

1. Bush K, Courvalin P, Dantas G, Davies J, Eisenstein B, Huovinen P, Jacoby GA, Kishony R, Kreiswirth BN, Kutter E, Lerner SA, Levy S, Lewis K, Lomovskaya O, Miller JH, Mobashery S, Piddock LJ, Projan S, Thomas CM, Tomasz A, Tulkens PM, Walsh TR, Watson JD, Witkowski J, Witte W, Wright G, Yeh P, Zgurskaya HI. 2011. Tackling antibiotic resistance. Nat. Rev. Microbiol. 9:894-896. http://dx.doi.org/10.1038/nrmicro2693.
2. Livermore DM. 2012. Fourteen years in resistance. Int. J. Antimicrob. Agents 39:283-294. http://dx.doi.org/10.1016/j.ijantimicag.2011.12.012.
3. Fisher J, Mobashery S. 2010. Enzymology of antibacterial resistance, p 443-487. In Mander L, Liu H (ed), Comprehensive natural products chemistry II. Elsevier, Oxford, United Kingdom.
4. Drawz SM, Bonomo RA. 2010. Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23:160-201. http://dx.doi.org/10.1128/CMR.00037-09.
5. Papp-Wallace KM, Bethel CR, Distler AM, Kasuboski C, Taracila M, Bonomo RA. 2010. Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A beta-lactamase. Antimicrob. Agents Chemother. 54:890-897. http://dx.doi.org/10.1128/AAC.00693-09.
6. Coleman K. 2011. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors. Curr. Opin. Microbiol. 14:550-555. http://dx.doi.org/10.1016/j.mib.2011.07.026.
7. Bonnefoy A, Dupuis-Hamelin C, Steier V, Delachaume C, Seys C, Stachyra T, Fairley M, Guitton M, Lampilas M. 2004. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54:410-417. http://dx.doi.org/10.1093/jac/dkh358. (Pubitemid 39177462)
8. Livermore DM, Mushtaq S, Warner M, Miossec C, Woodford N. 2008. NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J. Antimicrob. Chemother. 62:1053-1056. http://dx.doi.org/10.1093/jac/dkn320.
9. Stachyra T, Péchereau MC, Bruneau JM, Claudon M, Frère JM, Miossec C, Coleman K, Black MT. 2010. Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrob. Agents Chemother. 54:5132-5138. http://dx.doi.org/10.1128/AAC.00568- 10.
10. Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, Black MT. 2009. In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64:326-329. http://dx.doi.org/10.1093/ jac/dkp197.
11. Ehmann DE, Jahić H, Ross PL, Gu RF, Hu J, Kern G, Walkup GK, Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc. Natl. Acad. Sci. U. S. A. 109:11663-11668. http://dx.doi.org/10.1073/pnas.1205073109.
12. Ehmann DE, Jahic H, Ross PL, Gu RF, Hu J, Durand-Réville TF, Lahiri S, Thresher J, Livchak S, Gao N, Palmer T, Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J. Biol. Chem. 288:27960-27971. http://dx.doi.org/10.1074/jbc.M113.485979.
13. Xu H, Hazra S, Blanchard JS. 2012. NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry 51:4551-4557. http://dx.doi.org/10.1021/bi300508r.
14. Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M, De Luca F, Sanyal G, Docquier JD. 2013. Structural insight into potent broadspectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob. Agents Chemother. 57:2496-2505. http://dx.doi.org/10.1128/AAC.02247-12.
15. Castanheira M, Sader HS, Farrell DJ, Mendes RE, Jones RN. 2012. Activity of ceftaroline-avibactam tested against Gram-negative organism populations, including strains expressing one or more β-lactamases and methicillin-resistant Staphylococcus aureus carrying various staphylococcal cassette chromosome mec types. Antimicrob. Agents Chemother. 56:4779-4785. http://dx.doi.org/10.1128/AAC.00817-12.
16. Endimiani A, Choudhary Y, Bonomo RA. 2009. In vitro activity of NXL104 in combination with β-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases. Antimicrob. Agents Chemother. 53:3599-3601. http://dx.doi.org/10.1128/AAC.00641-09.
17. Mushtaq S, Warner M, Williams G, Critchley I, Livermore DM. 2010. Activity of chequerboard combinations of ceftaroline and NXL104 versus β-lactamase-producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1428-1432. http://dx.doi.org/10.1093/jac/dkq161.
18. Mushtaq S, Warner M, Livermore DM. 2010. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other nonfermenters. J. Antimicrob. Chemother. 65:2376-2381. http://dx.doi.org/10.1093/jac/dkq306.
19. Livermore DM, Mushtaq S, Warner M, Zhang J, Maharjan S, Doumith M, Woodford N. 2011. Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:390-394. http://dx.doi.org/10.1128/AAC.00756-10.
20. Lagacé-Wiens PR, Tailor F, Simner P, DeCorby M, Karlowsky JA, Walkty A, Hoban DJ, Zhanel GG. 2011. Activity of NXL104 in combination with β-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum β-lactamases and class C β-lactamases. Antimicrob. Agents Chemother. 55:2434-2437. http://dx.doi.org/10.1128/AAC.01722-10.
21. Levasseur P, Girard AM, Claudon M, Goossens H, Black MT, Coleman K, Miossec C. 2012. In vitro antibacterial activity of the ceftazi-dime- avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56:1606-1608. http://dx.doi.org/10.1128/AAC.06064- 11.
22. Crandon JL, Schuck VJ, Banevicius MA, Beaudoin ME, Nichols WW, Tanudra MA, Nicolau DP. 2012. Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidimeavibactam against Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 56:6137-6146. http://dx.doi.org/10. 1128/AAC.00851-12.
23. Louie A, Castanheira M, Liu W, Grasso C, Jones RN, Williams G, Critchley I, Thye D, Brown D, Vanscoy B, Kulawy R, Drusano GL. 2012. Pharmacodynamics of β-lactamase inhibition by NXL104 in combination with ceftaroline: examining organisms with multiple types of β-lactamases. Antimicrob. Agents Chemother. 56:258-270. http://dx.doi.org/10.1128/AAC.05005-11.
24. Aktaş Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 39:86-89. http://dx.doi.org/10.1016/j.ijantimicag.2011.09. 012.
25. Goldstein EJ, Citron DM, Merriam CV, Tyrrell KL. 2013. Comparative in vitro activity of ceftaroline, ceftaroline-avibactam, and other antimicrobial agents against aerobic and anaerobic bacteria cultured from infected diabetic foot wounds. Diagn. Microbiol. Infect. Dis. 76:347-351. http://dx.doi.org/10. 1016/j.diagmicrobio.2013.03.019.
26. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. 2011. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55:82-85. http://dx.doi.org/10.1128/AAC.01198-10.
27. Wiskirchen DE, Crandon JL, Furtado GH, Williams G, Nicolau DP. 2011. In vivo efficacy of a human-simulated regimen of ceftaroline combined with NXL104 against extended-spectrum-beta-lactamase (ESBL)-producing and non-ESBL-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55:3220-3225. http://dx.doi.org/10.1128/AAC.00024-11.
28. Borgonovi M, Merdjan H, Girard A, Levasseur P, Quernin J, Lowther J, Miossec C, Shlaes D, Drusano G. 2008. Importance of NXL-104 pharmacokinetics in the pharmacodynamics of ceftazidime-NXL-104 combinations, abstr A-023. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Washington, DC.
29. Nichols W, Levasseur P, Das S. 2012. A threshold concentration of avibactam (AVI) during the pharmacokinetic decline phase, below which β-lactamase inhibition in Enterobacteriaceae becomes ineffective, abstr A-1760. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
30. Bush K. 2012. Improving known classes of antibiotics: an optimistic approach for the future. Curr. Opin. Pharmacol. 12:527-534. http://dx.doi.org/ 10.1016/j.coph.2012.06.003.
31. Flückiger U, Segessenmann C, Gerber AU. 1991. Integration of pharmacokinetics and pharmacodynamics of imipenem in a human-adapted mouse model. Antimicrob. Agents Chemother. 35:1905-1910. http://dx.doi.org/10.1128/ AAC.35.9.1905.
32. Vazquez JA, González Patzán LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, Sable C. 2012. Efficacy and safety of ceftazidime-avibactam versus imipenemcilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 28:1921-1931. http://dx.doi.org/10.1185/03007995.2012.748653.
33. Azap OK, Arslan H, Serefhanoǧlu K, Colakoǧlu S, Erdoǧan H, Timurkaynak F, Senger SS. 2010. Risk factors for extended-spectrum β-lactamase positivity in uropathogenic Escherichia coli isolated from community-acquired urinary tract infections. Clin. Microbiol. Infect. 16:147-151. http://dx.doi.org/10.1111/j.1469-0691.2009.02941.x.
34. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intraabdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J. Antimicrob. Chemother. 68:1183-1192. http://dx.doi.org/10.1093/jac/dks523.
35. Citron DM, Tyrrell KL, Merriam V, Goldstein EJ. 2011. In vitro activity of ceftazidime-NXL104 against 396 strains of β-lactamase-producing anaerobes. Antimicrob. Agents Chemother. 55:3616-3620. http://dx.doi.org/10. 1128/AAC.01682-10.
36. Dubreuil LJ, Mahieux S, Neut C, Miossec C, Pace J. 2012. Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole. Int. J. Antimicrob. Agents 39: 500-504. http://dx.doi.org/10.1016/j.ijantimicag.2012.02.013.
37. Pucci MJ, Bush K. 2013. Investigational antimicrobial agents of 2013. Clin. Microbiol. Rev. 26:792-821. http://dx.doi.org/10.1128/CMR.00033-13.
38. Livermore DM, Mushtaq S, Barker K, Hope R, Warner M, Woodford N. 2012. Characterization of β-lactamase and porin mutants of Enterobacteriaceae selected with ceftaroline + avibactam (NXL104). J. Antimicrob. Chemother. 67:1354-1358. http://dx.doi.org/10.1093/jac/dks079.
39. Skalweit M, Li M, Conklin B, Taracila M. 2011. Effect of N152G, S and T substitution on CMY-2 β-lactamase activity and inhibition, abstr C1-601. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
40. Mangion IK, Ruck RT, Rivera N, Huffman MA, Shevlin M. 2011. A concise synthesis of a β-lactamase inhibitor. Org. Lett. 13:5480-5483. http://dx.doi.org/10.1021/ol202195n.
41. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. 2012. In vitro activity of MK-7655, a novel β-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gramnegative bacteria. Antimicrob. Agents Chemother. 56:3753-3757. http://dx.doi.org/10.1128/AAC.05927-11.
42. Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J. Antimicrob. Chemother. 68:2286-2290. http://dx.doi.org/10.1093/jac/dkt178.
43. Young K, Hackel M, Lascols C, Bouchillon S, Badal R, Martinez-Martinez L, Pillar C, Shinabarger D, Deane J, Sahm D. 2012. Response to imipenem plus MK-7655, a novel β-lactamase inhibitor, among 212 recent clinical isolates of P. aeruginosa, abstr 1620. Abstr. IDSA Week 2012, San Diego, CA.
44. Bhagunde P, Chang KT, Hirsch EB, Ledesma KR, Nikolaou M, Tam VH. 2012. Novel modeling framework to guide design of optimal dosing strategies for β-lactamase inhibitors. Antimicrob. Agents Chemother. 56:2237-2240. http://dx.doi.org/10.1128/AAC.06113-11.
45. Rizk M, Ahmed G, Young K, Motyl M, Butterton J, Racine F, Wu J, Li C, Wenning L. 2012. A semi-mechanistic pharmacokinetic/ pharmacodynamic (PK/PD) model for MK-7655, a novel β-lactamase inhibitor (BLI) for use in combination with imipenem/cilastatin, abstr A-1763. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
46. Köhler T, Michea-Hamzehpour M, Epp SF, Pechere JC. 1999. Carbapenem activities against Pseudomonas aeruginosa: respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43:424-427. (Pubitemid 29079192)
47. Strynadka NC, Martin R, Jensen SE, Gold M, Jones JB. 1996. Structure-based design of a potent transition state analogue for TEM-1 β-lactamase. Nat. Struct. Biol. 3:688-695. http://dx.doi.org/10.1038/ nsb0896-688. (Pubitemid 26260059)
48. Beesley T, Gascoyne N, Knott-Hunziker V, Petursson S, Waley SG, Jaurin B, Grundström T. 1983. The inhibition of class C β-lactamases by boronic acids. Biochem. J. 209:229-233. (Pubitemid 13153654)
49. Kiener PA, Waley SG. 1978. Reversible inhibitors of penicillinases. Biochem. J. 169:197-204. (Pubitemid 8270577)
50. Morandi S, Morandi F, Caselli E, Shoichet BK, Prati F. 2008. Structure-based optimization of cephalothin-analogue boronic acids as β-lactamase inhibitors. Bioorg. Med. Chem. 16:1195-1205. http://dx.doi.org/10.1016/j.bmc.2007.10.075. (Pubitemid 351191778)
51. Weston GS, Blázquez J, Baquero F, Shoichet BK. 1998. Structure-based enhancement of boronic acid-based inhibitors of AmpC β-lactamase. J. Med. Chem. 41:4577-4586. http://dx.doi.org/10.1021/ jm980343w. (Pubitemid 28516456)
52. Morandi F, Caselli E, Morandi S, Focia PJ, Blázquez J, Shoichet BK, Prati F. 2003. Nanomolar inhibitors of AmpC β-lactamase. J. Am. Chem. Soc. 125:685-695. http://dx.doi.org/10.1021/ja0288338.
53. Winkler ML, Rodkey EA, Taracila MA, Drawz SM, Bethel CR, Papp-Wallace KM, Smith KM, Xu Y, Dwulit-Smith JR, Romagnoli C, Caselli E, Prati F, van den Akker F, Bonomo RA. 2013. Design and exploration of novel boronic acid inhibitors reveals important interactions with a clavulanic acid-resistant sulfhydryl-variable (SHV) β-lactamase. J. Med. Chem. 56:1084-1097. http://dx.doi.org/10.1021/jm301490d.
54. Ke W, Sampson JM, Ori C, Prati F, Drawz SM, Bethel CR, Bonomo RA, van den Akker F. 2011. Novel insights into the mode of inhibition of class A SHV-1 β-lactamases revealed by boronic acid transition state inhibitors. Antimicrob. Agents Chemother. 55:174-183. http://dx.doi.org/10.1128/AAC.00930- 10.
55. Drawz SM, Babic M, Bethel CR, Taracila M, Distler AM, Ori C, Caselli E, Prati F, Bonomo RA. 2010. Inhibition of the class C β-lactamase from Acinetobacter spp.: insights into effective inhibitor design. Biochemistry 49:329-340. http://dx.doi.org/10.1021/bi9015988.
56. 4 carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase: insights into plasticity of the AmpC β-lactamase. Protein Sci. 20:941-958. http://dx.doi.org/10.1002/pro. 612.
57. Eidam O, Romagnoli C, Caselli E, Babaoglu K, Pohlhaus DT, Karpiak J, Bonnet R, Shoichet BK, Prati F. 2010. Design, synthesis, crystal structures, and antimicrobial activity of sulfonamide boronic acids as β-lactamase inhibitors. J. Med. Chem. 53:7852-7863. http://dx.doi.org/10.1021/jm101015z.
58. Tondi D, Calò S, Shoichet BK, Costi MP. 2010. Structural study of phenyl boronic acid derivatives as AmpC β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 20:3416-3419. http://dx.doi.org/10.1016/j.bmcl.2010.04.007.
59. Eidam O, Romagnoli C, Dalmasso G, Barelier S, Caselli E, Bonnet R, Shoichet BK, Prati F. 2012. Fragment-guided design of subnanomolar β-lactamase inhibitors active in vivo. Proc. Natl. Acad. Sci. U. S. A. 109: 17448-17453. http://dx.doi.org/10.1073/pnas.1208337109.
60. Baker M. 2013. Fragment-based lead discovery grows up. Nat. Rev. Drug Discov. 12:5-7. http://dx.doi.org/10.1038/nrd3926.
61. Livermore D, Mushtaq S, Dhanji H. 2012. Activity of RPX2003 - RPX7009 combinations against carbapenem-resistant Enterobacteriaceae, abstr F-853. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
62. Castanheira M, Becker H, Rhomberg P, Jones R. 2012. Pre-clinical evaluation of a carbapenem/β-lactamase inhibitor combination (RPX2003/RPX7009) tested against serine-carbapenemase-producing pathogens, abstr F-856. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
63. Sabet M, Tarazi Z, Lomovskaya O, Hecke S, Dudley M, Griffith O. 2012. In vivo efficacy of the β-lactamase inhibitor RPX7009 combined with the carbapenem RPX2003 against KPC-producing K. pneumoniae, abstr F-858. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
64. Hecker S, Reddy K, Totrov M, Hirst G, Sabet M, Tarazi Z, Dudley M. 2012. Discovery of RPX7009, a broad-spectrum β-lactamase inhibitor with utility vs. class A serine carbapenemase, abstr F-848. Abstr. Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA.
65. Livermore DM, Mushtaq S. 2013. Activity of biapenem (RPX2003) combined with the boronate β-lactamase inhibitor RPX7009 against carbapenem-resistant Enterobacteriaceae. J. Antimicrob. Chemother. 68: 1825-1831. http://dx.doi.org/10.1093/jac/dkt118.
66. Castanheira M, Konrardy M, Rhomberg P, Jones R. 2012. In vitro activity of a carbapenem and novel-β-lactamase inhibitor combination (RPX2003/RPX7009) tested against contemporary populations of Gram-negative organisms, abstr 1615. Abstr. ID Week 2012, San Diego, CA.
67. Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV. 2013. In vitro activity of biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria. Antimicrob. Agents Chemother. 57:2620-2630. http://dx.doi.org/10.1128/AAC.02418-12.
68. Johnson JW, Gretes M, Goodfellow VJ, Marrone L, Heynen ML, Strynadka NC, Dmitrienko GI. 2010. Cyclobutanone analogues of β-lactams revisited: insights into conformational requirements for inhibition of serine- and metallo-β-lactamases. J. Am. Chem. Soc. 132:2558-2560. http://dx.doi.org/ 10.1021/ja9086374.
69. Ke W, Bethel CR, Papp-Wallace KM, Pagadala SR, Nottingham M, Fernandez D, Buynak JD, Bonomo RA, van den Akker F. 2012. Crystal structures of KPC-2 β-lactamase in complex with 3-nitrophenyl boronic acid and the penam sulfone PSR-3-226. Antimicrob. Agents Chemother. 56:2713-2718. http://dx.doi.org/10.1128/AAC.06099-11.
70. Papp-Wallace KM, Bethel CR, Gootz TD, Shang W, Stroh J, Lau W, McLeod D, Price L, Marfat A, Distler A, Drawz SM, Chen H, Harry E, Nottingham M, Carey PR, Buynak JD, Bonomo RA. 2012. Inactivation of a class A and a class C β-lactamase by 6β-(hydroxymethyl)penicillanic acid sulfone. Biochem. Pharmacol. 83:462-471. http://dx.doi.org/10.1016/j.bcp.2011.11.015.
71. Bush K. 1998. Metallo-β-lactamases: a class apart. Clin. Infect. Dis. 27(Suppl 1):S48-S53. http://dx.doi.org/10.1086/514922.
72. Nordmann P, Poirel L, Walsh TR, Livermore DM. 2011. The emerging NDMcarbapenemases. Trends Microbiol. 19:588-595. http://dx.doi.org/10.1016/j. tim.2011.09.005.
73. Palzkill T. 2013. Metallo-β-lactamase structure and function. Ann. N. Y. Acad. Sci. 1277:91-104. http://dx.doi.org/10.1111/j.1749-6632.2012.06796. x.
74. Poeylaut-Palena AA, Tomatis PE, Karsisiotis AI, Damblon C, Mata EG, Vila AJ. 2007. A minimalistic approach to identify substrate binding features in B1 metallo-β-lactamases. Bioorg. Med. Chem. Lett. 17:5171-5174. http://dx.doi.org/10.1016/j.bmcl.2007.06.089. (Pubitemid 47259655)
75. García-Saez I, Hopkins J, Papamicael C, Franceschini N, Amicosante G, Rossolini GM, Galleni M, Frère JM, Dideberg O. 2003. The 1.5-A structure of Chryseobacterium meningosepticum zinc β-lactamase in complex with the inhibitor, D-captopril. J. Biol. Chem. 278:23868-23873. http://dx.doi.org/10.1074/jbc.M301062200. (Pubitemid 36830213)
76. Liénard BM, Garau G, Horsfall L, Karsisiotis AI, Damblon C, Lassaux P, Papamicael C, Roberts GC, Galleni M, Dideberg O, Frère JM, Schofield CJ. 2008. Structural basis for the broad-spectrum inhibition of metallo-β-lactamases by thiols. Org. Biomol. Chem. 6:2282-2294. http://dx.doi.org/10.1039/b802311e. (Pubitemid 351852832)
77. King DT, Worrall LJ, Gruninger R, Strynadka NC. 2012. New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition. J. Am. Chem. Soc. 134:11362-11365. http://dx.doi.org/10.1021/ ja303579d.
78. Heinz U, Bauer R, Wommer S, Meyer-Klaucke W, Papamichaels C, Bateson J, Adolph HW. 2003. Coordination geometries of metal ions in d- or l-captopril-inhibited metallo-β-lactamases. J. Biol. Chem. 278: 20659-20666. http://dx.doi.org/10.1074/jbc.M212581200. (Pubitemid 36806366)
79. Maltezou HC. 2009. Metallo-β-lactamases in Gram-negative bacteria: introducing the era of pan-resistance?. Int. J. Antimicrob. Agents 33: 405.e1-405.e7. http://dx.doi.org/10.1016/j.ijantimicag.2008.09.003.
80. Cornaglia G, Riccio ML, Mazzariol A, Lauretti L, Fontana R, Rossolini GM. 1999. Appearance of IMP-1 metallo-β-lactamase in Europe. Lancet 353:899-900. http://dx.doi.org/10.1016/S0140-6736(98)05954-6.
81. VIM, a new integron-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob. Agents Chemother. 43:1584-1590.
82. Irwin JJ, Raushel FM, Shoichet BK. 2005. Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry 44:12316-12328. http://dx.doi.org/10.1021/bi050801k. (Pubitemid 41324325)
83. Widmann M, Pleiss J, Oelschlaeger P. 2012. Systematic analysis of metallo-β-lactamases using an automated database. Antimicrob. Agents Chemother. 56:3481-3491. http://dx.doi.org/10.1128/AAC.00255-12.
84. Oelschlaeger P, Ai N, Duprez KT, Welsh WJ, Toney JH. 2010. Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J. Med. Chem. 53:3013-3027. http://dx.doi.org/10.1021/jm9012938.
85. Vella P, Hussein WM, Leung EW, Clayton D, Ollis DL, Mitić N, Schenk G, McGeary RP. 2011. The identification of new metallo-β-lactamase inhibitor leads from fragment-based screening. Bioorg. Med. Chem. Lett. 21:3282-3285. http://dx.doi.org/10.1016/j.bmcl.2011.04.027.
86. Mohamed MS, Hussein WM, McGeary RP, Vella P, Schenk G, Abd El-Hameed RH. 2011. Synthesis and kinetic testing of new inhibitors for a metallo-β- lactamase from Klebsiella pneumoniae and Pseudomonas aeruginosa. Eur. J. Med. Chem. 46:6075-6082. http://dx.doi.org/10.1016/j.ejmech.2011.10.030.
87. Faridoon Hussein WM, Vella P, Islam NU, Ollis DL, Schenk G, McGeary RP. 2012. 3-Mercapto-1,2,4-triazoles and N-acylated thiosemicarbazides as metallo-β-lactamase inhibitors. Bioorg. Med. Chem. Lett. 22:380-386. http://dx.doi.org/10.1016/j.bmcl.2011.10.116.
88. Aoki N, Ishii Y, Tateda K, Saga T, Kimura S, Kikuchi Y, Kobayashi T, Tanabe Y, Tsukada H, Gejyo F, Yamaguchi K. 2010. Efficacy of calcium-EDTA as an inhibitor for metallo-β-lactamase in a mouse model of Pseudomonas aeruginosa pneumonia. Antimicrob. Agents Chemother. 54:4582-4588. http://dx.doi.org/10.1128/AAC.00511-10.
89. Yoshizumi A, Ishii Y, Livermore DM, Woodford N, Kimura S, Saga T, Harada S, Yamaguchi K, Tateda K. 2013. Efficacies of calcium-EDTA in combination with imipenem in a murine model of sepsis caused by Escherichia coli with NDM-1 β-lactamase. J. Infect. Chemother. 19:992-995. http://dx.doi.org/10.1007/ s10156-012-0528-y.
90. Laraki N, Franceschini N, Rossolini GM, Santucci P, Meunier C, de Pauw E, Amicosante G, Frère JM, Galleni M. 1999. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-β-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43:902-906. (Pubitemid 29165755)
91. Bush K, Jacoby GA, Medeiros AA. 1995. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob. Agents Chemother. 39:1211-1233. http://dx.doi.org/10.1128/AAC.39.6.1211.
92. Lee K, Lim YS, Yong D, Yum JH, Chong Y. 2003. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-β-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 41:4623-4629. http://dx.doi.org/10.1128/ JCM.41.10.4623-4629.2003. (Pubitemid 37259767)
93. Pitout JD, Gregson DB, Poirel L, McClure JA, Le P, Church DL. 2005. Detection of Pseudomonas aeruginosa producing metallo-β-lactamases in a large centralized laboratory. J. Clin. Microbiol. 43:3129-3135. http://dx.doi.org/10.1128/JCM.43.7.3129-3135.2005. (Pubitemid 40981312)
94. Vaara M. 1992. Agents that increase the permeability of the outer membrane. Microbiol. Rev. 56:395-411.
95. Banin E, Brady KM, Greenberg EP. 2006. Chelator-induced dispersal and killing of Pseudomonas aeruginosa cells in a biofilm. Appl. Environ. Microbiol. 72:2064-2069. http://dx.doi.org/10.1128/AEM.72.3.2064-2069.2006.
96. Lamas GA, Goertz C, Boineau R, Mark DB, Rozema T, Nahin RL, Lindblad L, Lewis EF, Drisko J, Lee KL, TACT Investigators. 2013. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 309:1241-1250. http://dx.doi.org/10. 1001/jama.2013.2107.
97. Falagas ME, Karageorgopoulos DE, Nordmann P. 2011. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes. Future Microbiol. 6:653-666. http://dx.doi.org/10.2217/fmb.11.49.
98. Centers for Disease Control and Prevention. 2006. Deaths associated with hypocalcemia from chelation therapy-Texas, Pennsylvania, and Oregon, 2003-2005. JAMA 295:2131-2134. http://dx.doi.org/10.1001/jama.295.18.2131.
99. Franz KJ. 2013. Clawing back: broadening the notion of metal chelators in medicine. Curr. Opin. Chem. Biol. 17:143-149. http://dx.doi.org/10.1016/j.cbpa. 2012.12.021.
100. Agrawal A, DeSoto J, Fullagar JL, Maddali K, Rostami S, Richman DD, Pommier Y, Cohen SM. 2012. Probing chelation motifs in HIV integrase inhibitors. Proc. Natl. Acad. Sci. U. S. A. 109:2251-2256. http://dx.doi.org/10.1073/pnas. 1112389109.
101. Naas T, Nordmann P. 1999. OXA-type β-lactamases. Curr. Pharm. Des. 5:865-879.
102. Jacoby GA, Munoz-Price LS. 2005. The new β-lactamases. N. Engl. J. Med. 352:380-391. http://dx.doi.org/10.1056/NEJMra041359.
103. Héritier C, Poirel L, Aubert D, Nordmann P. 2003. Genetic and functional analysis of the chromosome-encoded carbapenemhydrolyzing oxacillinase OXA-40 of Acinetobacter baumannii. Antimicrob. Agents Chemother. 47:268-273. http://dx.doi.org/10.1128/AAC.47.1.268-273.2003. (Pubitemid 36070374)
104. Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54:969-976. http://dx.doi.org/10.1128/AAC.01009-09.
105. Poirel L, Naas T, Nordmann P. 2010. Diversity, epidemiology, and genetics of classD β-lactamases. Antimicrob. Agents Chemother. 54:24-38. http://dx.doi.org/10.1128/AAC.01512-08.
106. Patel G, Bonomo RA. 2013. "Stormy waters ahead": global emergence of carbapenemases. Front. Microbiol. 4:48. http://dx.doi.org/10.3389/ fmicb.2013.00048.
107. Drawz SM, Bethel CR, Doppalapudi VR, Sheri A, Pagadala SR, Hujer AM, Skalweit MJ, Anderson VE, Chen SG, Buynak JD, Bonomo RA. 2010. Penicillin sulfone inhibitors of class D β-lactamases. Antimicrob. Agents Chemother. 54:1414-1424. http://dx.doi.org/10.1128/AAC.00743-09.
108. Bou G, Santillana E, Sheri A, Beceiro A, Sampson JM, Kalp M, Bethel CR, Distler AM, Drawz SM, Pagadala SR, van den Akker F, Bonomo RA, Romero A, Buynak JD. 2010. Design, synthesis, and crystal structures of 6-alkylidene-2′- substituted penicillanic acid sulfones as potent inhibitors of Acinetobacter baumannii OXA-24 carbapenemase. J. Am. Chem. Soc. 132:13320-13331. http://dx.doi.org/10.1021/ja104092z.
109. Tan Q, Ogawa AM, Painter RE, Park YW, Young K, DiNinno FP. 2010. 4,7-Dichloro benzothien-2-yl sulfonylaminomethyl boronic acid: first boronic acid-derived β-lactamase inhibitor with class A, C, and D activity. Bioorg. Med. Chem. Lett. 20:2622-2624. http://dx.doi.org/10.1016/j.bmcl.2010.02.065.
110. Tan Q, Ogawa AM, Raghoobar SL, Wisniewski D, Colwell L, Park YW, Young K, Hermes JD, Dininno FP, Hammond ML. 2011. Thiophenyl oxime-derived phosphonates as nano-molar class C β-lactamase inhibitors reducing MIC of imipenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Bioorg. Med. Chem. Lett. 21:4363-4365. http://dx.doi.org/10.1016/j.bmcl.2011.04.122.
111. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67:1597-1606. http://dx.doi.org/10. 1093/jac/dks121.
112. Héritier C, Poirel L, Lambert T, Nordmann P. 2005. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acinetobacter baumannii. Antimicrob. Agents Chemother. 49: 3198-3202. http://dx.doi.org/10.1128/AAC.49.8.3198-3202.2005. (Pubitemid 41060561)
113. Queenan AM, Bush K. 2007. Carbapenemases: the versatile β-lactamases. Clin. Microbiol. Rev. 20:440-458. http://dx.doi.org/10.1128/ CMR.00001-07.
114. Bradford PA. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. http://dx.doi.org/10.1128/ CMR.14.4.933-951.2001. (Pubitemid 32979636)
115. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin. Microbiol. Rev. 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
116. Shlaes DM. 2013. New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann. N. Y. Acad. Sci. 1277:105-114. http://dx.doi.org/10.1111/nyas.12010.
117. Higgins PG, Stefanik D, Page MG, Hackel M, Seifert H. 2012. In vitro activity of the siderophore monosulfactam BAL30072 against meropenem-non- susceptible Acinetobacter baumannii. J. Antimicrob. Chemother. 67:1167-1169. http://dx.doi.org/10.1093/jac/dks009.
118. Buynak JD. 2013. β-Lactamase inhibitors: a review of the patent literature (2010-2013). Expert. Opin. Ther. Pat. 23:1469-1481. http://dx.doi.org/10.1517/13543776.2013.831071.
119. Boucher HW, Talbot GH, Benjamin DK, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D, Infectious Diseases Society of America. 2013. 10 x '20 progress- development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. Clin. Infect. Dis. 56:1685-1694. http://dx.doi.org/10.1093/cid/cit152.
120. Infectious Diseases Society of America. 2012. White paper: recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drugresistant bacterial pathogens. Clin. Infect. Dis. 55:1031-1046. http://dx.doi.org/10.1093/cid/cis688.
121. Spellberg B, Bartlett JG, Gilbert DN. 2013. The future of antibiotics and resistance. N. Engl. J. Med. 368:299-302. http://dx.doi.org/10.1056/ NEJMp1215093.
122. Shlaes DM, Sahm D, Opiela C, Spellberg B. 2013. The FDA reboot of antibiotic development. Antimicrob. Agents Chemother. 57:4605-4607. http://dx.doi.org/10.1128/AAC.01277-13.
123. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, Shirwadkar C, Eastwood GM, Myburgh J, Paterson DL, Lipman J. 2013. Continuous infusion of β-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin. Infect. Dis. 56:236-244. http://dx.doi.org/10.1093/cid/cis856.
124. Drusano GL, Lodise TP. 2013. Saving lives with optimal antimicrobial chemotherapy. Clin. Infect. Dis. 56:245-247. http://dx.doi.org/10.1093/cid/ cis863.